Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168779 · ClinicalTrials.gov registry record · Phase 4
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,185
- Enrollment target
NCT00168779 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,185 participants.
The verdict
NCT00168779, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,185 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
Interventions
- DRUG placebo
- DRUG telmisartan 80 mg / hydrochlorothiazide 25 mg
- DRUG valsartan 160 mg / hydrochlorothiazide 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,185 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168779
The ClinicalTrials.gov registry entry for NCT00168779 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00168779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168779 about?
NCT00168779 is a clinical study titled "Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension". The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
What is the current status of trial NCT00168779?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,185 participants. The study started on 2005-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00168779?
The interventions under investigation include: placebo (DRUG), telmisartan 80 mg / hydrochlorothiazide 25 mg (DRUG), valsartan 160 mg / hydrochlorothiazide 25 mg (DRUG).
Who is sponsoring clinical trial NCT00168779?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.